Recently, a novel therapy with burosumab, a kind of humanized monoclonal anti-FGF23 antibody, has been approved for the treatment of XLHR patients over 1 year of age in Europe and US, with the function of increasing renal phosphate reabsorption and normalizing serum phosphate [15, 24]. This evidence concerns the gene FGF23 and X-linked dominant hypophosphatemic rickets.